IMR Press / FBL / Volume 23 / Issue 3 / DOI: 10.2741/4605

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Immune ligands for cytotoxic T Lymphocytes (CTLS) in cancer stem cells (CSCS)

Show Less
1 Division of Medical Oncology, Department of Internal Medicine, Sault Area Hospital, Sault Ste Marie, Ontario, Canada, and Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, Ontario, Canada
Front. Biosci. (Landmark Ed) 2018, 23(3), 563–583; https://doi.org/10.2741/4605
Published: 1 January 2018
(This article belongs to the Special Issue Cancer immunology and immunotherapy)
Abstract

The immune system has come to the forefront of cancer therapeutics in recent years with the success of immune blockade inhibitors in a variety of cancers whose list is increasing with a quick pace. Despite the efficacy of these drugs across a significant part of the cancer spectrum, responses are still seen only in a minority of patients, that implies that most patients are refractory or promptly develop resistance to these agents. Mechanisms of this resistance are important to decipher as this knowledge may lead to the introduction of additional therapies or manipulations to modulate resistance. The cancer stem cell theory stipulates that a minority of cancer cells in a given tumor are responsible for self-renewal and bulk tumor propagation. These cells, in most instances, are rare and less proliferative but give rise to highly proliferative progeny. In addition, they are, in general, resistant to therapies and endowed with metastatic potential through a process called EMT (Epithelial to Mesenchymal Transition). Cancer stem cells resistance to treatments may relate to inherent insensitivity to external apoptotic stimuli and, thus, may extend to immune therapies by inhibiting the actions of Cytotoxic T Lymphocytes (CTLs) in the tumor micro-environment. This paper examines available data on expression and regulation of immune co-modulatory (co-stimulatory and co-inhibitory) ligands on cancer stem cells in order to devise strategies to circumvent resistance.

Keywords
Cancer stem cells
Immune Ligands
Immune Receptors
Activating
Inhibitory
Cytotoxic T lymphocytes
Tumor Antigen Presentation
Proteasome
Review
Share
Back to top